The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) technology to develop potential ...